Fitzmaurice C, Abate D, Abbasi N, et al. - In this systematic analysis, researchers used the Global Burden of Disease (GBD) study estimation methods to report cancer burden for 29 cancer groups in 195 countries from 1990 through 2017, focusing on cancer incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life-years (DALYs), to offer the data required for cancer control planning. Cancer-attributable incident cases were 24.5 million (16.8 million without nonmelanoma skin cancer) in 2017, and cancer-attributable deaths and DALYs were 9.6 million and 233.5 million, respectively, during this time period. Between 2007 and 2017, a rise by 33% was noted in the incident cases, with the lowest rise seen in the most developed countries. Neoplasms increased among the top reasons for DALYs from the sixth to the second place between 1990 and 2017. Large heterogeneities were displayed by the national epidemiological profiles of cancer burden in the GBD study, which is indicative of different exposures to risk factors, economic settings, lifestyles, and access to care and screening. To reach the global targets and enhance equity in cancer care, policy makers and other stakeholders can use the GBD study for developing and improving national and local cancer control.